



STEPS TO USING THE PRODUCT

1

Preparation. Dilute the desired dose (1 mL per 2 kg of body weight) into Lactated Ringer's solution to obtain a total administration volume of 1 liter. Warm solution to body temperature prior to administration. Shake well before using.

2

Administration. When West Nile Virus is suspected, prompt administration is recommended. Slowly administer intravenously using aseptic technique.

3

Storage. Store out of direct sunlight at 35 to 45 degrees F. Use the entire contents when first opened. Do not freeze.

4

Anaphylactic reactions. To reduce the risk of anaphylactic reactions, premedicate with flunixin meglumine (1.1 mg/kg). Anaphylactic reactions are unlikely, but may occur. If they do, treat symptoms with epinephrine.

EDUCATING YOUR CLIENTS ABOUT WEST NILE VIRUS


You can help your clients keep their horses safe from the West Nile Virus by:

- Encouraging them to stay current on their West Nile Virus vaccination schedule
- Emphasizing management steps to reduce mosquitoes, thereby decreasing the chances of exposure to West Nile Virus
- Asking them to watch for and contact you upon notice of any of these clinical signs of West Nile Virus infection:
 - Ataxia (stumbling or incoordination)
 - Depression or apprehension
 - Weakness of limbs
 - Partial paralysis
 - Muscle twitching
- Informing them of the *West Nile Virus Antibody* – a product to combat disease caused by the West Nile Virus

To learn more about the West Nile Virus Antibody, contact Novartis Animal Health US, Inc. at www.livestock.novartis.com or call 1-800-843-3386.



www.livestock.novartis.com
© 2004 Novartis Animal Health US, Inc.



West Nile Virus Antibody:

Take Control of the West Nile Virus



1 Shimoni Zvi, et al. (2001). Treatment of West Nile Virus Encephalitis with Intravenous Immunoglobulin. *Emerging Infectious Diseases*, Vol. 7, No. 4.

2 Hamdan A, et al. (2002). Possible Benefit of Intravenous Immunoglobulin Therapy in a Lung Transplant Recipient with West Nile Virus Encephalitis. *Transplant Infectious Disease*, Vol. 4, pp 160-162.



The West Nile Virus was seen in horses in 42 states in 2003, with 5,181 equine cases reported. Of those, almost one-third died or were euthanized.

Yet, when it comes to caring for horses that contract this threatening mosquito-borne illness, veterinarians have had to rely on limited supportive therapies to address the symptoms.



Until now.

Novartis Animal Health has responded to this urgent need by bringing a *West Nile Virus Antibody (Equine Origin)* to the equine industry. The USDA issued a conditional license for the product for use in yearling or older horses as an aid in the control of disease caused by the virus.

Cornell University analyzed the *West Nile Virus Antibody* and conducted serum neutralization testing and neutralizing index studies on post-administration serum samples. This research demonstrated a rise in the neutralizing serological antibody to the West Nile Virus following antibody administration. Based on the study, researchers concluded there is a reasonable expectation of efficacy when the *West Nile Virus Antibody* is administered to horses that have been potentially exposed to the virus.

Field studies involving 106 horses of varying ages and breeds demonstrated the product is safe when used according to label directions.

With the West Nile Virus, so much is at stake. You can use the *West Nile Virus Antibody* with confidence – knowing you have prescribed a safe product that specifically targets the West Nile Virus.

WHY USE IMMUNOGLOBULINS?

Novartis Animal Health is a leader in animal biologicals, including immunoglobulin products. Also known as an antibody or antiserum, immunoglobulins provide immediate, short-term protection through artificially acquired passive immunity.

The injection of immunoglobulins provides disease-specific antibodies to neutralize a specific antigen – without challenging the immune system. When an animal needs antibodies instantly, immunoglobulins are an excellent choice.

The use of immunoglobulin products has been common in both human and animal medicine for decades. In fact, in human health, the use of an antibody product has played a significant role in reducing the severity and duration of symptoms and recovery of human patients affected with West Nile Virus.^{1,2}

Similarly, the use of the *West Nile Virus Antibody* in horses will help aid in the control of the disease caused by West Nile Virus by providing high quality,

neutralizing IgG immunoglobulins immediately upon administration. A neutralizing index study of post-administration serum samples by Cornell University demonstrated the ability of the *West Nile Virus Antibody* to neutralize the West Nile Virus.

WHEN TO USE WEST NILE VIRUS ANTIBODY

Disease outbreak occurs in an animal that has not been vaccinated. When an unvaccinated horse shows signs of illness from exposure to West Nile Virus, it's too late for a vaccine to stimulate the immune system. *West Nile Virus Antibody* can be used as an aid in the control of disease caused by the virus.

An animal was vaccinated but still contracts the West Nile Virus. This can be the case if the horse was incubating the disease when it was vaccinated, or if its immune system is compromised. The *West Nile Virus Antibody* can provide the animal with immediate, short-term immunity to the disease challenge.

WHY USE THE WEST NILE VIRUS ANTIBODY?

- One-third of horses demonstrating clinical signs of West Nile Virus infection have died or were euthanized
- West Nile Virus Antibody* focuses specifically on this virus and is licensed for use in yearling or older horses as an aid in the control of disease caused by the West Nile Virus
- West Nile Virus Antibody* allows you to target the actual disease-causing agent rather than being limited to symptomatic treatments
- Field studies demonstrate it's safe when used according to directions
- Manufactured by Novartis Animal Health US, Inc., a leader in biological innovations

